, élargir l'arsenal thérapeutique, notamment avec le nivolumab. Cependant son utilisation chez les sujets âgés a très peu été étudiée lors des études pivots CheckMate 017 et 057. Une étude rétrospective de l
, er février 2015 et le 30 décembre 2018 sur les données de toxicité, d'efficacité et d'arrêts précoces chez le sujet âgé
, De plus notre étude a permis de mettre en avant qu'un IMC faible pouvait être lié à la survenue de toxicité (p = 0,05), de même que les patients présentant des métastases hépatiques étaient moins fréquemment exposés aux toxicités, L'analyse des données de toxicité révèle une fréquence plus importante dans notre population comparativement aux données des études pivots avec notamment des fréquences de toxicité cutanée, vol.2, p.0
, 5 mois vs 2,56 mois) et de SG (11,3 mois vs 11,1 mois) globalement équivalentes. L'analyse multivariée des données de survie met en évidence différents paramètres pouvant influer la réponse au nivolumab : il ressort de cette étude plusieurs facteurs influençant la SSP et la SG : l'utilisation de cisplatine dans les cures, L'analyse des données d'efficacité est comparable aux données des études pivots notamment avec des médianes de SSP
, De même, l'absence d'association d'une antibiothérapie, corticothérapie et/ou IPP au nivolumab ressort comme un facteur protecteur de progression, vol.07, p.0
, Concernant les arrêts précoces, l'analyse multivariée révèle que le nivolumab en 2 ème ligne est un facteur de risque d
, Néanmoins, l'utilisation de cisplatine dans les cures précédant le nivolumab apparaît comme un facteur protecteur d'arrêts précoces
, De plus, certains facteurs biologiques tels qu'un taux de CRP (p = 0,0281), de globules blancs (p = 0,0003) et de polynucléaires neutrophiles
Cancer statistics, CA Cancer J Clin. févr, vol.66, issue.1, pp.7-30, 2016. ,
,
,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014. ,
, KEYTRUDA (pembrolizumab, p.26
,
nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review, Ann Oncol Off J Eur Soc Med Oncol, vol.25, issue.10, pp.1914-1922, 2014. ,
Polymedication among elderly patients Preventing drug related problems and inappropriate medication ,
, J Pharm Belg. sept, issue.3, pp.4-9, 2016.
, L'Institut publie L'essentiel des faits et chiffres des cancers en France (édition 2019) -Actualités
France métropolitaine : projections d'incidence et de mortalité par cancer en, 2017. ,
Évolution épidémiologique du cancer broncho-pulmonaire en France et en Europe, Rev Mal Respir Actual. 1 sept, vol.5, issue.5, pp.321-325, 2013. ,
,
,
, Le cancer du poumon -Les cancers les plus fréquents
,
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.11, issue.10, pp.1653-71, 2016. ,
, Cancer du poumon : points-clés -Cancer du poumon
,
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, J Thorac Oncol. 1 août, vol.2, issue.8, pp.706-720, 2007. ,
Définition classification TNM ,
, , p.49, 2017.
Tobacco as a cause of lung cancer: some reflections, Am J Epidemiol, vol.146, issue.9, pp.687-94, 1997. ,
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?, Ann Oncol Off J Eur Soc Med Oncol. avr, vol.26, issue.4, pp.779-86, 2015. ,
Evidence for a major gene effect in early-onset lung cancer, J La State Med Soc Off Organ La State Med Soc. avr, vol.145, issue.4, pp.157-62, 1993. ,
Dietary heterocyclic amines and the risk of lung cancer among Missouri women, Cancer Res. 15 juill, vol.60, issue.14, pp.3753-3759, 2000. ,
Adjustment for tobacco smoking and alcohol consumption by simultaneous analysis of several types of cancer. Cancer Causes Control CCC, vol.28, pp.155-65, 2017. ,
Lung cancer surgery: acceptable morbidity and mortality, expected results and quality control, Surg Oncol. déc, vol.11, issue.4, pp.263-269, 2002. ,
, Traitements du cancer du poumon non à petites cellules -Société canad
, Cancer bronchique non à petites cellules -Référentiel national de RCP -Ref : RECOKBRNONPETCEL15 [Internet
Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review, Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al, vol.194, issue.2, pp.79-90, 2018. ,
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer, Thorax. avr, vol.70, issue.4, pp.359-67, 2015. ,
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy, Lung Cancer Amst Neth, vol.110, pp.7-13, 2017. ,
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors, Cancer Immunol Immunother CII. mars, vol.68, issue.3, pp.341-52, 2019. ,
,
,
,
,
,
,
,
nivolumab plus ipilimumab in non-small-cell lung cancer, Future Oncol Lond Engl. 8 mai, 2019. ,
Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells, Nat Immunol. mars, vol.2, issue.3, pp.255-60, 2001. ,
Les cellules natural killer, 2008. ,
,
Immunité anti-tumorale et thérapies cellulaires du cancer. médecine/sciences, janv, vol.19, issue.1, pp.43-53, 2003. ,
Présentation antigénique par les cellules dendritiques. médecine/sciences, vol.15, p.931, 1999. ,
Cancer vaccines, Nat Med. mai, vol.4, issue.5, pp.525-556, 1998. ,
Regulatory T cells: key controllers of immunologic self-tolerance, Cell. 26 mai, vol.101, issue.5, pp.455-463, 2000. ,
The host-tumor immune conflict: from immunosuppression to resistance and destruction, Immunol Today. oct, vol.18, issue.10, pp.493-500, 1997. ,
Tumorspecific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma, Cancer Res. 15 sept, vol.61, issue.18, pp.6838-6883, 2001. ,
URL : https://hal.archives-ouvertes.fr/hal-00092851
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science. 25 mars, vol.331, issue.6024, pp.1565-70, 2011. ,
Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002. ,
Immunité antitumorale (mécanismes, immunoediting, immunosurveillance), vol.17, 2015. ,
Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. médecine/sciences, vol.27, pp.842-851, 2011. ,
Influence de PD-1 sur la synapse immunologique -Une facette de la régulation immunitaire ? médecine/sciences. 1 déc, vol.29, pp.1080-1082, 2013. ,
Immunothérapies anti-checkpoints : aspects fondamentaux, MISE AU POINT, vol.6, 2018. ,
, NCI Dictionary of Cancer Terms, 2011.
,
,
,
10 mg/ml sol diluer p perf -Prescription / délivrance / prise en charge ,
Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01981595
,
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol. 1 juill, vol.28, issue.suppl_4, pp.119-161, 2017. ,
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis, J Am Acad Dermatol. sept, vol.69, issue.3, pp.121-128, 2013. ,
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer. avr, vol.21, issue.2, pp.371-81, 2014. ,
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype, Acta Diabetol. avr, vol.56, issue.4, pp.441-449, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02195223
nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases, Ann Oncol Off J Eur Soc Med Oncol. 1 avr, vol.29, issue.4, pp.959-65, 2018. ,
, Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers. 5 mars, vol.11, issue.3, 2019.
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treat Rev. avr, vol.45, pp.7-18, 2016. ,
, Les inhibiteurs des points de contrôle de l immunité -PDF
,
nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol Off J Am Soc Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017. ,
First-Line nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.25, pp.2415-2441, 2017. ,
Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227, J Clin Oncol. 20 mai, vol.36, issue.15_suppl, pp.9001-9001, 2018. ,
02c-026 Is nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153, J Thorac Oncol. janv, vol.12, issue.1, pp.1287-1295, 2017. ,
1303PDnivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ?70 years and with poor performance status, Ann Oncol, issue.1, 2017. ,
, NHIS -Adult Tobacco Use -Glossary
,
nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer, J Geriatr Oncol. sept, vol.9, issue.5, pp.494-500, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02152681
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors, Ann Oncol Off J Eur Soc Med Oncol. 1 août, vol.28, issue.8, pp.2002-2010, 2017. ,
Factors associated with sarcopenia in institutionalized elderly. Nutr Hosp. 30 mars, vol.34, pp.345-51, 2017. ,
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients, Invest New Drugs, vol.35, issue.4, pp.436-477, 2017. ,
Skeletal muscle cells actively shape (auto)immune responses, Autoimmun Rev. mai, vol.17, issue.5, pp.518-547, 2018. ,
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab, J Immunother Cancer. 10 juill, vol.7, issue.1, p.176, 2019. ,
, Les antibiotiques perturbent l'efficacité de l'immunothérapie
, , 2017.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science. 5 janv, vol.359, issue.6371, pp.91-98, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01727917
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann Oncol Off J Eur Soc Med Oncol. 1 juin, vol.29, issue.6, pp.1437-1481, 2018. ,
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with nivolumab, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.13, issue.11, pp.1771-1776, 2018. ,
1323PBaseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients, Ann Oncol, issue.1, 2017. ,
, Efficacy of PD-1/PD-L1 therapy: Do proton pump inhibitors affect the outcome?, Journal of Clinical Oncology, vol.86
, PPIS Therapy Negatively Impacts the Efficacy of nivolumab | ESMO
,
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis, Cancer Treat Rev. avr, vol.45, pp.30-37, 2016. ,
Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?, Expert Rev Vaccines. févr, vol.11, issue.2, pp.167-76, 2012. ,
Immunity in the elderly: the role of the thymus, J Comp Pathol. janv, vol.142, issue.1, pp.111-115, 2010. ,
Age-related deregulation of naive T cell homeostasis in elderly humans, Age. juin, vol.33, issue.2, pp.197-207, 2011. ,
Role of T lymphocyte replicative senescence in vaccine efficacy, Vaccine. 8 janv, vol.25, issue.4, pp.599-604, 2007. ,
An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans, J Gerontol A Biol Sci Med Sci. mai, vol.60, issue.5, pp.556-65, 2005. ,
Reduced naïve CD8+ T-cell priming efficacy in elderly adults, Aging Cell. févr, vol.15, issue.1, pp.14-21, 2016. ,
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, issue.3, pp.143-52, 2017. ,
nivolumabrefractory patients with advanced non-small-cell lung cancer, Lung Cancer Amst Neth. avr, vol.130, pp.128-162, 2019. ,
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy, JAMA Oncol, vol.4, issue.11, pp.1543-52, 2018. ,
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with nivolumab, Anticancer Res, vol.37, issue.10, pp.5857-62, 2017. ,
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer. 1 avr, vol.106, pp.1-7, 2017. ,
Performance Status in Patients With Cancer, JAMA Oncol, vol.1, issue.7, pp.998-998, 2015. ,
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases, Ann Oncol. 1 juill, vol.27, issue.7, pp.1354-1360, 2016. ,
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer Amst Neth, vol.106, pp.1-7, 2017. ,
Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl Lek Listy, vol.102, issue.1, pp.5-14, 2001. ,
Immunomonitoring and prognostic relevance of neutrophils in clinical trials, Semin Cancer Biol. 1 juin, vol.23, issue.3, pp.200-207, 2013. ,
nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Oncotarget, vol.22, issue.47, pp.77404-77419, 2016. ,
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer, Oncotarget, vol.8, issue.61, pp.103117-103145, 2017. ,
,
, Zhejiang Xue Xue Bao Yi Xue Ban, J Zhejiang Univ Med Sci. 25 déc, vol.47, issue.6, pp.659-64, 2018.
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With nivolumab, Clin Lung Cancer, vol.19, issue.2, pp.171-177, 2018. ,
The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer, Oncotarget. 31 janv, vol.8, issue.5, pp.8835-8877, 2017. ,